New and emerging treatments for ulcerative colitis: a focus on vedolizumab

Tamsin Gledhill,1 Keith Bodger21Digestive Diseases Centre, Aintree University Hospital Trust, 2Gastroenterology Department, Institute of Translational Medicine, University of Liverpool, Liverpool, UKAbstract: Ulcerative colitis (UC) is the most common form of chronic inflammatory bowel disease and l...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gledhill T, Bodger K
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://doaj.org/article/df0a4f9f36d540c88a56d09b35666d56
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:df0a4f9f36d540c88a56d09b35666d56
record_format dspace
spelling oai:doaj.org-article:df0a4f9f36d540c88a56d09b35666d562021-12-02T07:21:21ZNew and emerging treatments for ulcerative colitis: a focus on vedolizumab1177-54751177-5491https://doaj.org/article/df0a4f9f36d540c88a56d09b35666d562013-05-01T00:00:00Zhttp://www.dovepress.com/new-and-emerging-treatments-for-ulcerative-colitis-a-focus-on-vedolizu-a13121https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Tamsin Gledhill,1 Keith Bodger21Digestive Diseases Centre, Aintree University Hospital Trust, 2Gastroenterology Department, Institute of Translational Medicine, University of Liverpool, Liverpool, UKAbstract: Ulcerative colitis (UC) is the most common form of chronic inflammatory bowel disease and lacks a curative pharmacological treatment. Traditional therapies, which include 5-aminosalicylates, corticosteroids and immunosuppressants, aim to induce and maintain remission. Biological therapy with anti-tumor necrosis factor-alpha agents has added to the range of available treatments. Vedolizumab belongs to a new class of agents (integrin antagonists) that inhibit leukocyte adhesion and aim to selectively inhibit the inflammatory pathway. This article reviews the emerging data on the use of vedolizumab for UC. Evidence to date supports its efficacy in inducing remission in UC, with no major safety concerns identified.Keywords: inflammatory bowel disease, effectiveness, integrin antagonistsGledhill TBodger KDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2013, Iss default, Pp 123-130 (2013)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Gledhill T
Bodger K
New and emerging treatments for ulcerative colitis: a focus on vedolizumab
description Tamsin Gledhill,1 Keith Bodger21Digestive Diseases Centre, Aintree University Hospital Trust, 2Gastroenterology Department, Institute of Translational Medicine, University of Liverpool, Liverpool, UKAbstract: Ulcerative colitis (UC) is the most common form of chronic inflammatory bowel disease and lacks a curative pharmacological treatment. Traditional therapies, which include 5-aminosalicylates, corticosteroids and immunosuppressants, aim to induce and maintain remission. Biological therapy with anti-tumor necrosis factor-alpha agents has added to the range of available treatments. Vedolizumab belongs to a new class of agents (integrin antagonists) that inhibit leukocyte adhesion and aim to selectively inhibit the inflammatory pathway. This article reviews the emerging data on the use of vedolizumab for UC. Evidence to date supports its efficacy in inducing remission in UC, with no major safety concerns identified.Keywords: inflammatory bowel disease, effectiveness, integrin antagonists
format article
author Gledhill T
Bodger K
author_facet Gledhill T
Bodger K
author_sort Gledhill T
title New and emerging treatments for ulcerative colitis: a focus on vedolizumab
title_short New and emerging treatments for ulcerative colitis: a focus on vedolizumab
title_full New and emerging treatments for ulcerative colitis: a focus on vedolizumab
title_fullStr New and emerging treatments for ulcerative colitis: a focus on vedolizumab
title_full_unstemmed New and emerging treatments for ulcerative colitis: a focus on vedolizumab
title_sort new and emerging treatments for ulcerative colitis: a focus on vedolizumab
publisher Dove Medical Press
publishDate 2013
url https://doaj.org/article/df0a4f9f36d540c88a56d09b35666d56
work_keys_str_mv AT gledhillt newandemergingtreatmentsforulcerativecolitisafocusonvedolizumab
AT bodgerk newandemergingtreatmentsforulcerativecolitisafocusonvedolizumab
_version_ 1718399486889295872